Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):307–313. doi: 10.1097/QAI.0b013e3182511e42

Table 3A.

Effect of anthelminthic treatment on HIV-1 load

A. Six weeks post-treatment

Group Mean (SE) log10 HIV load at
baselinea
Mean (SE) log10 HIV load at
six weeks post-treatment
Crude mean
difference (95% CI)
Adjusted mean
difference (95% CI)b
p
Placebo Albendazole Placebo Albendazole

All women 4.21 (0.11) 3.92 (0.10) 4.26 (0.10) 3.85 (0.09) −0.40 (−0.68, −0.13) −0.17 (−0.36, 0.01) 0.07
Hookworm infected 4.32 (0.18) 3.99 (0.18) 4.18 (0.16) 3.85 (0.16) −0.33 (−0.77, 0.11) −0.12 (−0.46, 0.22) 0.44c
Hookworm uninfected 4.13 (0.13) 3.88 (0.13) 4.31 (0.13) 3.85 (0.12) −0.46 (−0.81, −0.10) −0.22 (−0.44, −0.01)

Placebo Praziquantel Placebo Praziquantel

All women 4.08 (0.10) 4.05 (0.11) 4.06 (0.09) 4.05 (0.11) −0.01 (−0.29, 0.27) 0.01 (−0.18, 0.20) 0.94
S. mansoni infected 3.89 (0.22) 4.17 (0.27) 3.80 (0.22) 4.12 (0.27) 0.32 (−0.38, 1.02) 0.07 (−0.27, 0.41) 0.56c
S. mansoni uninfected 4.11 (0.11) 4.02 (0.12) 4.11 (0.10) 4.03 (0.12) −0.08 (−0.39, 0.23) −0.02 (−0.24, 0.20)
a

For those with viral load measured at six weeks post-treatment

b

For effect of albendazole treatment, results were adjusted for baseline viral load, baseline malaria parasitaemia and viral load assay used at six weeks; for effect of praziquantel treatment, results were adjusted for baseline viral load

c

Interaction p-value

SE=standard error;CI=confidence interval